Mutagenic Assessment of Olmesartan Cilexetil by Bacterial Mutation Assay
Toxicological Research
;
: 217-219, 2013.
Article
in English
| WPRIM
| ID: wpr-193671
ABSTRACT
Hypertension is a serious health problem due to high frequency and concomitant other diseases including cardiovascular and renal dysfunction. Olmesartan cilexetil is a new antihypertensive drug associated with angiotensin II receptor antagonist. This study was conducted to evaluate the mutagenicity of olmesartan cilexetil by bacterial reverse mutation test using Salmonella typhimurium (TA100, TA1535, TA98, and TA1537) and Escherichia coli (WP2 uvrA). At the concentrations of 0, 62, 185, 556, 1667, and 5000 microg/plate, olmesartan cilexetil was negative in both Salmonella typhimurium and Escherichia coli regardless of presence or absence of metabolic activation system (S9 mix). These results demonstrate that olmesartan cilexetil does not induce bacterial reverse mutation.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Salmonella typhimurium
/
Tetrazoles
/
Receptors, Angiotensin
/
Biotransformation
/
Escherichia coli
/
Hypertension
/
Imidazoles
Language:
English
Journal:
Toxicological Research
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS